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Abstract 
Abstract 
Review on t(1;12)(q11-21;p11-13), with data on 
clinics. 
Clinics and pathology 
Disease 
Myeloid disorders, less frequently multiple myeloma 
and lymphoid malignancies 
Note 
The balanced t(1;12)(q21;p13) translocation results 
in a ETV6 / ARNT fusion gene. 
Phenotype/cell stem origin 
16 cases with an unbalanced sex ratio (11 males/5 
females aged 0 to 79-years old).  
Most cases were diagnosed with myeloid 
malignancies (10 patients; 7 males and 3 females 
aged 0 to 72 years old): 3 patients with refractory 
anemia (RA) (Pedersen-Bjergaard et al., 1998; 
Andersen et al., 2005; Gerr et al., 2006), among them 
2 were treated for multiple myeloma (MM) 
(Pedersen-Bjergaard et al., 1998; Andersen et al., 
2005) and 7 patients were diagnosed with acute 
myeloid leukemia (AML) (Trent et al., 1983;  La 
Starza et al., 1999;  Odero et al., 2001; Andersen et 
al., 2005; Fitzgibbon et al., 2005; Raghavan et al., 
2005; Gerr et al., 2006; Tuborgh et al., 2013;  Parihar 
et al., 2014).  
The AML cases were most often M5 AML (5/7) and 
in this small AML M5 series, 3 cases are found in 
infant patients. 3 cases were diagnosed with multiple 
myeloma (Calasanz et al., 1997;  González et al., 
2004; Gabrea et al., 2008) and 3 with lymphoid 
malignancies: chronic lymphocytic leukemia (CLL) 
(Miyamoto et al., 1981),  Burkitt's lymphoma 
(Schoch et al., 1995) and  mature B-cell neoplasm 
(Kuroda et al., 2000) (Table 1).  
Prognosis 
Unknown; may be unfavorable in association with 
complex karyotypes and in association with poor-
risk genetic features. 
Cytogenetics 
Cytogenetics morphological 
Unbalanced rearrangement; breakpoint has been 
defined on 1q to be between q11-q21; breakpoints in 
12p are heterogeneous (assigned to chromosome 
bands from 12p11 to p13);  most of cases reported 
12p13 breakpoint (9 out of 16 cases).  
Sole aberration in 3 AML patients (Trent et al., 1983; 
Fitzgibbon et al., 2005; Raghavan et al., 2005) and 
part of a complex karyotype in the remaining AML 
cases that are associated with +8 in 3 (La Starza et 
al., 1999; Gerr et al., 2006; Tuborgh et al., 2013) and 
11q23 aberration in 2 patients (Odero et al., 2001; 
Tuborgh et al., 2013).  Found in complex karyotypes 
and in association with t(11;14)(q13;q32) in 1 MM 
patient (Calasanz et al., 1997) and with 8q24 
rearrangement in both lymphoma cases (Schoch et 
al., 1995; Kuroda et al., 2000). 
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Sex/Age Disease Karyotype  Ref. 
 Myeloid neoplasms  
M/72 AML 46,XY,der(12)t(1;12)(q21;p13)   1 






M/55 AML-M6 48,XY,+8,der(12)t(1;12)(q21;p13),+mar/48,idem,add(7)(q?)   3 







dic(7;13)(p11;p11), der(12)t(1;12)(q21;p13)  
 5 
M AML-M5 46,XY,der(12)t(1;12)(q11;p11)  6 
M AML-M5 46,XY,der(12)t(1;12)(q11;p11)   7 










F/1 AML-M5 46,XX,der(12)t(1;12)(q12;p13)/46,XX,der(13)t(1;13)(q12;p12)  10 









 B-cell neoplasms  






48,XX,t(8;22)(q24;q11),der(12)t(1;12)(q21;p13),+17,+mar   16 
Table 1. Abbreviations: Ref, reference; M, male; F, female; AML, acute myeloid leukemia; RA, refractory anemia; MM, multiple 
myeloma; RAEB, refractory anemia with excess of blasts; CLL, chronic  lymphocytic leukemia; BL, Burkitt's lymphoma. 
References: 1. Trent et al., 1983; 2.  Pedersen-Bjergaard et al., 1998; 3. La  Starza et al., 1999; 4. Odero et al., 2001; 5. 
Andersen et al., 2005; 6.  Fitzgibbon et al., 2005; 7. Raghavan et al., 2005; 8. Gerr et al., 2006; 9.  Tuborgh et al., 2013; 10. 
Parihar et al.,  2014; 11. Calasanz et al., 1997; 12. González et al., 2004; 13. Gabrea et al.,  2008; 14. Miyamoto et al., 1981; 15. 
Schoch et al., 1995; 16. Kuroda et al., 2000. 
 
Genes involved and 
proteins 
This unbalanced translocation is likely to be 
molecularly heterogeneous and whether the same 
gene(s) are involved in both myeloid and lymphoid 
malignancies is unknown. 




Unbalanced translocations between the long arm of 
chromosome 1 and the short arm of chromosome 12 
are infrequent but might be relatively specific to 
myeloid-lineage malignancies. Although 
cytogenetically heterogeneous, der(12)t(1;12)(q11-
21;p11-13) results in a gain of 1q leading to genomic 
imbalances. Gains/amplification of 1q are common 
in a broad spectrum of myeloid and lymphoid 
haematological malignancies indicating that that 
genes of the 1q region may provide selective growth 
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advantages for the leukemic cells  in a variety of 
neoplasms.  
The unbalanced der(12)t(1;12)(q11-21;p11-13) may 
be present as the sole anomaly or in association with 
complex karyotypes, implicating that it may have a 
key role in disease initiation and/or progression. 
Alternatively, it is possible that genes on the 12p11-
p13 region may also be involved in disease 
pathogenesis either as a result of the chromosome 
translocation and/or deletions. Notably, 
chromosome 12 breakpoint in der(12)t(1;12)(q11-
21;p11-13) is most often localized on 12p13, that 
include the TEL/ETV6 gene, therefore it is possible 
that ETV6 may be affected by the translocation, at 
least in some patients. In addition, 12p 
rearrangements are frequently accompanied by small 
interstitial deletions that include ETV6 and 
CDKN1B among other genes. Thus, 
haploinsufficiency or loss of tumor suppressor 
function of genes located on the 12p11-p13 region 
may play a role in oncogenesis. Whether genes 
located on the 12p11-p13 region are involved in this 
aberration has not been determined. 
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